文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

beti-cel基因治疗输血依赖型β地中海贫血的长期疗效与安全性

Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia.
PubMed 文献 · Blood · 2026-01-01

beti-cel基因治疗在63例输血依赖型β地中海贫血患者中显示持久疗效:III期90.2%达输血非依赖,中位Hb 11.2 g/dL;长期随访未报告恶性肿瘤或插入性致癌。

要点

  • III期90.2%患者达输血非依赖,中位Hb 11.2 g/dL
  • 52例达标者中73%停用铁螯合,肝铁浓度未增加
  • 无恶性肿瘤、插入性致癌或复制 competent 慢病毒报告

核心结论

  • beti-cel是一次性持久疗法,可实现输血非依赖、恢复铁平衡并改善生活质量。
  • III期制造工艺优化后输血非依赖率高于I/II期。

研究设计与样本

  • 63例输血依赖型β地中海贫血患者接受beti-cel,中位年龄17岁(范围4-35岁)。
  • I/II期22例,III期41例,均入组长期随访LTF-303研究,中位随访5.9年(范围2.9-10.1年)。

主要发现

  • I/II期15/22(68.2%)达输血非依赖,中位加权平均Hb 10.2 g/dL。
  • III期37/41(90.2%)达输血非依赖,中位Hb 11.2 g/dL,并持续至末次随访。
  • 疗效在各年龄和TDT基因型间相似。
  • 52例达输血非依赖者中38例(73%)末次随访时停用铁螯合,肝铁浓度未增加。
  • 无效造血标志物(血清转铁蛋白受体和促红细胞生成素)改善,生活质量评分持久提升。

关键数值与推荐

  • III期输血非依赖率90.2%(37/41),中位Hb 11.2 g/dL。
  • I/II期输血非依赖率68.2%(15/22),中位加权平均Hb 10.2 g/dL。
  • 达输血非依赖者73%(38/52)停用铁螯合。

临床怎么用

  • beti-cel可作为输血依赖型β地中海贫血的潜在治愈性一次治疗选择。
  • 治疗后需长期随访监测输血非依赖状态、铁代谢和安全性。

局限性

  • 长期随访中位5.9年,更远期安全性仍需持续观察。
  • I/II期与III期制造工艺不同,疗效数据需分层解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Betibeglogene autotemcel (beti-cel) gene therapy for transfusion-dependent β-thalassemia (TDT) involves autologous transplantation of hematopoietic stem and progenitor cells transduced with a modified β-globin gene to produce functional adult hemoglobin (Hb) containing βA-T87Q-globin (HbAT87Q). Sixty-three participants with TDT (median age, 17 years [range, 4-35]) received beti-cel in phase 1/2 (n = 22) or phase 3 (n = 41) studies and enrolled in the long-term follow-up LTF-303 study (median follow-up, 5.9 years [range, 2.9-10.1]). Manufacturing refinements in phase 3 increased transduction efficiency, resulting in higher drug product vector copy number and HbAT87Q levels, which translated into higher Hb and transfusion independence (TI) rates than in phase 1/2. TI was achieved by 15 of 22 (68.2%) phase 1/2 participants (median weighted average Hb during TI, 10.2 g/dL) and 37 of 41 (90.2%) of phase 3 participants (median, 11.2 g/dL), and was sustained through last follow-up. Treatment efficacy was similar across ages and TDT genotypes. Among participants achieving TI, 38 of 52 (73%) had discontinued iron chelation at last follow-up, with no increase in liver iron concentration. Markers of ineffective erythropoiesis, including serum transferrin receptor and erythropoietin, improved with restoration of iron homeostasis. Health-related quality-of-life assessment scores showed durable improvements. No malignancies, insertional oncogenesis, or vector-derived replication-competent lentivirus were reported. These findings establish beti-cel as a durable, 1-time therapy that achieves TI, restores iron balance, and improves quality of life, offering a potentially curative treatment option for people with TDT. This trial was registered at www.clinicaltrials.gov as NCT02633943.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kwiatkowski JL, Thompson AA, Schneiderman J, et al. Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia. Blood. 2026. PMID: 41525466. doi:10.1182/blood.2025029196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。